Clinical effectiveness and cost-consequences of selective serotonin reuptake inhibitors in the treatment of sex offenders

Health Technology Assessment

Volumn 6, Issue 28, 2002, Pages

  Adi, Y ^a   Ashcroft, D ^a   Browne, K ^a   Beech, A ^a   Fry Smith, A ^a   Hyde, C ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; CYPROTERONE ACETATE; FEMOXETINE; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; HORMONE; IFOXETINE; MEDROXYPROGESTERONE ACETATE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VIQUALINE;

ABDOMINAL DISEASE; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; ANXIETY DISORDER; ASTHENIA; BODY WEIGHT DISORDER; CASTRATION; CHILD SEXUAL ABUSE; CLINICAL TRIAL; CONVULSION; COST BENEFIT ANALYSIS; DATA BASE; DEPRESSION; DROWSINESS; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; ECONOMIC ASPECT; EMBASE; EVIDENCE BASED MEDICINE; FANTASY; GALACTORRHEA; GYNECOMASTIA; HALLUCINATION; HEADACHE; HEPATITIS; HUMAN; INCIDENCE; INFERTILITY; INSOMNIA; INTERNET; JAUNDICE; LIVER CANCER; LIVER DYSFUNCTION; LIVER FAILURE; MASTURBATION; MEDLINE; MYALGIA; NERVOUSNESS; OFFENDER; OSTEOPOROSIS; OUTCOMES RESEARCH; PHOTOSENSITIVITY DISORDER; PREVALENCE; PSYCINFO; PUBLIC HEALTH; QUALITATIVE ANALYSIS; RELAPSE; REVIEW; SEDATION; SEXUAL ABUSE; SEXUAL AROUSAL; SEXUAL BEHAVIOR; SEXUAL CRIME; SEXUAL DEVIATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN DISEASE; STATISTICAL SIGNIFICANCE; TREMOR; UNITED KINGDOM; URTICARIA; VASCULITIS; VERTIGO; XEROSTOMIA;

EID: 0036451001     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta6280     Document Type: Review

References (110)

1. Soothill K, Walby S. Sex crime in the news. London: Routledge; 1991.
2. White P, Bradley C, Ferriter M, Hatzipetrou L. Managements for people with disorders of sexual preference and for convicted sexual offenders (Cochrane Review). In: The Cochrane Library. Issue 2. Oxford: Update Software; 2000.
3. Home Office. A Review of Classification Systems for Sex Offenders. London: Home Office; 1998. Report No.: Home Office research findings 78.
4. Home Office. Recorded Crime Statistics 1898-2001. [cited 2001 Nov 12]. http://www.homeoffice.gov.uk/rds/pdfs/100years.xls
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Revision. 4th ed. Washington, DC: American Psychiatric Association; 2000.
6. McCann IL, Sakheim DK, Abrahamson DJ. Trauma and victimisation: A model of psychological adaptation. The Counselling Psychologist 1998;16:531-94.
7. Home Office. Recorded Crime Statistics, England and Wales. 1/00 ed. London: Home Office; 1998.
8. Prior V, Glaser D, Lynch MA. Responding to child sexual abuse: The criminal justice system. Child Abuse Rev 1997;6:128-40.
9. Elliot M, Browne K, Kilcoyne J. Child sexual abuse prevention: What offenders tell us. Child Abuse Neglect 1995;19:579-94.
10. Beech A, Friendship C, Erikson M, Hanson RK. The relationship between static and dynamic risk factors and reconviction in a sample of UK child abusers. 2001. Sexual Abuse: J Res Treatment 2002;14:155-68.
11. Marshall P. The prevalence of convictions for sexual offending. Home Office Research and Statistics Directorate Research Findings. 55th ed. London: Home Office; 1997.
12. National Statistics Office. Cautions, Court Proceedings and Sentencing, England and Wales, 2000. London: National Statistics Office; 2000.
13. Harris J, Grace S. A Question of Evidence? Investigating and Prosecuting Rape in the 1990s. London: Information and Publications Group; 1999.
14. Home Office. Prison Statistics England and Wales, 2000. London: The Stationery Office Limited; 2000.
15. Creighton S. Recognising changes in incidence and prevalence. In: Browne K, Hanks H, Stratton P, Hamilton C, editors. Early Prediction and Prevention of Child Abuse: A Handbook. Chichester: John Wiley & Sons; 2002.
16. Cawson P, Wattam C, Brooker S, Kelly G. Child Maltreatment in the United Kingdom: A Study of the Prevalence of Child Abuse and Neglect. London: NSPCC; 2000.
17. Department of Health. Children and Young Persons on Child Protection Registers Year Ending 31st March 2000. London: Government Statistical Service; 2000.
18. Greenfeld LA. Sex Offenses and Offenders. An Analysis of Data on Rape and Sexual Assault. Washington, DC: US Department of Justice; 1997.
19. Beech A, Fisher D, Beckett R. Step 3: An Evaluation of the Prison Sex Offender Treatment Programme. London: Home Office; 1998.
20. Mann RE. Pravention: Offensive gegen sexuellen kindesmibbrauch. In: Hofling S, Drewes D, Epple-Waigel I, editors. The Sex Offender Treatment Programme; HM Prison Service. Munich: Atwerbverlag KG Publikation; 1999. p. 346-52.
21. Marshall WL, Anderson D, Fernandez Y. Cognitive Behavioural Treatment of Sexual Offenders. Chichester: John Wiley & Sons; 1999.
22. Alexander M. Sexual offenders treatment efficacy revisited. Sexual Abuse: J Res Treatment 1999;11:101-16.
23. Beech A, Fordham A. Therapeutic climate of sexual offender treatment programmes. Sexual Abuse: J Res Treatment 1997;9:219-37.
24. Hanson RK, Thornton D. Improving risk assessments for sexual offenders: A comparison of three actuarial scales. Law Hum Behav 2000;24:119-136.
25. Hall GC. Sex offender recidivism revisited: A meta-analysis of recent treatment studies. J Consulting Clin Psychol 1995;63:802-9.
26. Marshall WL, Jones R, Ward T, Johnson P, Barbaree HE. Treatment outcome with sex offenders. Clin Psychol Rev 1991;11(465):485.
27. Bradford JM. The antiandrogen and hormonal treatment of sex offenders. In: Marshall WL, Barbaree HE, editors. Handbook of Sexual Assault: Issues, Theories and Treatment of the Offenders. New York: Plenum Press; 1990. p. 297-310.
28. Royal Pharmaceutical Society. Martindale - The Extra Pharmacopoeia. 31st ed. London: Royal Pharmaceutical Society; 1996.
29. Prentky RA, Quinsey VL. Organic Treatment for the Male Sexual Offender. Human Sexual Aggression: Current Perspectives. New York: Annals of the New York Academy of Sciences; 1988. p. 193-202.
30. Cooper M. Setting Standards and Guiding Principles for the Assessment, Treatment and Management of Sex Offenders in British Columbia. Vancouver: BC Institute on Family Violence; 1994.
31. Langevin R. Sexual anomalies in the brain. In: Marshall WL, Barbaree HE, editors. Handbook of Sexual Assault: Issues, Theories and Treatment of the Offenders. New York: Plenum Press; 1990. p. 103-13.
32. Ward T, Hudson SM. A model of the relapse process in sexual offenders. J Interpersonal Violence 1998;13:700-25.
33. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary 41. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain; 2001.
34. Preskorn SH. Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors. Caddo: Professional Communications Inc; 1996.
35. Tork I. Anatomy of the serotonergic system. In: Peroutka S, Whitaker-Azmitia P, editors. Neuropharmacology of Serotonin. New York: Annals of the New York Academy of Science; 1990. p. 9-35.
36. Hoyer D, Clark DE, Fozard JR. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157-203.
37. Bradford JMW. The paraphilias, obsessive compulsive spectrum disorder and the treatment of sexually deviant behaviour. Psychiatr Q 1999;70:209-19.
38. Modell JG, Katholi CR, Modell JD, DePalma RL. Comparative sexual side effects of bupropion, fluoxetine, paroxetine and sertraline. Clin Pharmacol Ther 1997;61:476-87.
39. Lorrain D, Riolo J, Matuszewich L, Hull E. Lateral hypothalamic serotonin inhibits nucleas accumbens dopamine: Implications for sexual satiety. J Neurosci 1999;19:7648-52.
40. Kafka MP. The role of medications in the treatment of paraphilia-related disorders: Psychopharmacological treatments for non-paraphilic compulsive sexual behaviours: A review. Sexual Relationship Ther 2001;16:105-12.
41. Kuzel R. Management of depression. Current trends in primary care. Postgrad Med 185;99:179-80.
42. Maixner SM, Greden JF. Extended antidepressant maintenance and discontinuation syndromes. Depression Anxiety 1998;8 Suppl 1:43-53.
43. Haddad P. Newer antidepressants and the discontinuation syndrome. J Clin Psychiatry 1997;58(7)17-22.
44. Price JS, Waller PC, Wood SM, Mackay AVP. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996;42:757-63.
45. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996;16:356-62.
46. Marshall WL, Barbaree HE. Outcome of comprehensive cognitive-behavioural treatment programs. In: Marshall WL, Laws DR, Barbaree HE, editors. Handbook of Sexual Assault: Issues, Theories, and Treatment of the Offender. New York: Plenum Press; 1990. p. 363-85.
47. Hanson RK, Bussiere M.T. Predicting relapse: A meta-analysis of sexual offender recidivism studies. J Consultancy Clin Psychol 1998;66:348-62.
48. Lloyd C, Mair G, Hough M. Explaining Reconviction Rates: A Critical Analysis. 1994.
49. Morrison T, Erooga M, Beckett RL. Adult Sex Offenders: Who are they? Why and how do they do it? Sexual Offending Against Children: Assessment and Treatment of Male Abusers. London: Routledge; 1994. p. 1-24.
50. Barker M, Morgan R. Sex Offenders: A Framework for the Evaluation of Community-based Treatment. London: HMSO; 1993.
51. Barbaree H. Evaluating treatment efficacy with sexual offenders. Sexual Abuse: J Res Treatment 1997;9:111-29.
52. Colledge M, Collier P, Brand S. Programmes for Offenders: Guidance for Evaluators. London: Research, Development and Statistics Directorate, Home Office; 1999.
53. Cochrane Reviewers Handbook. 4.1.4 ed. Oxford: Update Software; 2001.
54. NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness. CRD's Guidance for Those Carrying Out or Commissioning Reviews. CRD Report No. 4 (second edition). York: University of York; 2001.
55. Coleman E, Cesnick J, Moore A, Dwyer S. An exploratory study of the role of psychotropic medications in the treatment of sex offenders. J Offender Rehabilitation 1992;18(75):88.
56. Perilstein R, Lipper S, Friedman L. Three cases of paraphilias responsive to fluoxetine treatment. J Clin Psychiatry 1991;52:169-70.
57. Stein D, Hollander E, Anthony D, Schneier FR, Fallon B, Liebowitz M, et al. Serotonergic medications for sexual obsessions, sexual addictions and paraphilias. J Clin Psychiatry 1992;53:267-71.
58. Kafka M, Prentky R. Fluoxetine treatment of nonparaphilic sexual addictions and paraphilias in men. J Clin Psychiatry 1992;53:351-8.
59. Kafka M. Sertraline pharmacotherapy for paraphilias and paraphilia-related disorders: An open trial. Ann Clin Psychiatry 1994;6:189-95.
60. Bradford J.M. An open pilot study of sertraline in the treatment of outpatients with pedophilia. Paper presented at the: 1995 Annual Congress of the American Psychiatric Association; 1995 May 24; Miami, Florida.
61. Fedoroff J.P. Antiandrogens vs serotonergic medications in the treatment of sex offenders: A preliminary compliance study. Can J Hum Sexuality 1995;4:111-23.
62. Greenberg D, Bradford J, Curry S, O'Rourke A. A comparison of treatment of paraphilias with three serotonin reuptake inhibitors: A retrospective study. Bull Am Acad Psychiatry Law 1996;24:525-32.
63. Kafka M, Hennen J. Psychostimulant augmentation during treatment with selective serotonin reuptake inhibitors in men with paraphilias and paraphilia-related disorders: A case series. J Clin Psychiatry 2000;61:664-70.
64. Mauskopf JA, Paul JE, Grant DM, Stergachis A. The role of cost-consequences analysis in healthcare decision-making. Pharmacoeconomics 1998;13:277-88.
65. Prentky R, Burgess A. Rehabilitation of child molesters: A cost-benefit analysis. Am J Orthopsychiatry 1990;60:108-17.
66. Donato R, Shanahan M. The economics of child sex offender rehabilitation programs: Beyond Prentky & Burgess. Am J Orthopsychiatry 2001;71:31-9.
67. Shanahan M, Donato R. Counting the cost: Estimating the economic benefit of paedophile treatment programs. Child Abuse Neglect 2001;25:541-55.
68. Monthly Index of Medical Specialities. London: Haymarket Medical Ltd; 2002.
69. National Health Service England and Wales. Drug Tariff. London: The Stationery Office; 2002.
70. Abouesh A, Clayton A. Compulsive voyeurism and exhibitionism: A clinical response to paroxetine. Arch Sexual Behav 1999;28(1).
71. Aguirre B. Fluoxetine and compulsive sexual behavior. J Am Acad Child Adolesc Psychiatry 1999;38:943.
72. Serotonin in various psychiatric diseases: Depression, neurosis and sexual deviation. Therapiewoche 1992;42:274-5.
73. Balon R. Pharmacological treatment of paraphilias with a focus on antidepressants. J Sex Marital Ther 1998;24:241-54.
74. Becker JV. Sexual deviance. Curr Opin Psychiatry 1992;5:788-91.
75. Bianchi MD. Fluoxetine treatment of exhibitionism. Am J Psychiatry 1990;147:1089-90.
76. Bourgeois JA, Klein M. Risperidone and fluoxetine in the treatment of pedophilia with comorbid dysthymia. J Clin Psychopharmacol 1996;16:257-8.
77. Bradford JMW, Gratzer TG. A treatment for impulse control disorders and paraphilia: A case report. Can J Psychiatry 1995;40:4-5.
78. Bradford JMW. The role of serotonin in the future of forensic psychiatry. Bull Am Acad Psychiatry Law 1996;24:57-72.
79. Bradford JMW. The treatment of sexual deviation using a pharmacological approach. J Sex Res 2000;37:248-57.
80. Bradford JMW. The neurobiology, neuropharmacology and pharmacological treatment of the paraphilias and compulsive sexual behaviour. Can J Psychiatry 1901;46:26-34.
81. Butterfield MI, Panzer PG, Forneris CA. Victimization of women and its impact on assessment and treatment in the psychiatric emergency setting. Psychiatr Clinics North Am 1999;22:875-96.
82. Coleman E, Gratzer T. Nesvacil L, Raymond N. Nefazodone and the treatment of nonparaphilic compulsive sexual behavior: A retrospective study. J Clin Psychiatry 2000;61:282-4.
83. Duggan C. Sexual crime. Curr Opin Psychiatry 1998;11:663-7.
84. Emmanuel NP, Lydiard RB, Ballenger JC. Fluoxetine treatment of voyeurism. Am J Psychiatry 1991;148:950.
85. Galli V. Raute N, McConville B, McElroy S. An adolescent male with multiple paraphilias successfully treated with fluoxetine. J Child Adolesc Psychopharmacol 1998;8:195-7.
86. Gijs L, Gooren L. Hormonal and psychopharmacological interventions in the treatment of paraphilias: An update. J Sex Res 1996;33:273-90.
87. Greenberg DM, Bradford JMW. Treatment of the paraphilic disorders: A review of the role of the selective serotonin reuptake inhibitors. Sexual Abuse: J Res Treatment 1997;9:349-60.
88. Grossman LS, Martis B, Fichtner C. Are sex offenders treatable? A research overview. Psychiatr Serv 1999;50:349-61.
89. Haywood T, Cavanaugh JL. Sexual deviancy. Curr Opin Psychiatry 1996;9:384-8.
90. Hollander E, Wong CM. Body dysmorphic disorder, pathological gambling and sexual compulsions. J Clin Psychiatry 1995;56 Suppl 4: 7-12.
91. Hollander E. Obsessive-compulsive disorder-related disorders: The role of selective serotonergic reuptake inhibitors. Int Clin Psychopharmacol 1996; 11 Suppl 5:75-87.
92. Hollander E, Rosen J. Impulsivity. J Psychopharmacol 2000;14(2 Suppl 1):S39-44.
93. Kafka MP. Successful antidepressant treatment of nonparaphilic sexual addictions and paraphilias in men. J Clin Psychiatry 1991;52:60-5.
94. Kafka MP. Successful treatment of paraphilic coercive disorder (a rapist) with fluoxetine hydrochloride. Br J Psychiatry 1991;158:844-7.
95. Kapka MP. Paraphilia-related disorders - Common, neglected and misunderstood. Harv Rev Psychiatry 1994;2:39-40.
96. Kafka MP. Current concepts in the drug treatment of paraphilias and paraphilia-related disorders. CNS Drugs 1995;3:9-21.
97. Lane RM. A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction; incidence, possible aetiology and implications for management. J Psychopharmacol 1997;11:72-82.
98. Lehne G, Thomas K, Berlin F. Treatment of sexual paraphilias: A review of the 1999-2000 literature. Curr Opin Psychiatry 2000;13:569-73.
99. Lehrman NS, Shabry FR, Jorgensen VT. Cross-dressing successfully treated with fluoxetine. N Y State J Med 1991;91:171.
100. Levitsky AM, Owens NJ. Pharmacologic treatment of hypersexuality and paraphilias in nursing home residents. J Am Geriatrics Soc 1999;47:231-4.
101. Lorefice L. Fluoxetine treatment of a fetish. J Clin Psychiatry 1991;52:41.
102. Meisler JG, Myers W, Watter D. Sexual addiction: A new phenomenon? J Women's Health 1998;7:163-5.
103. Messiha FS. Fluoxetine: A spectrum of clinical applications and postulates of underlying mechanisms. Neurosci Biobehav Rev 1993;17:385-96.
104. Richer M, Crison L. Pharmacotherapy of sexual offenders. Ann Pharmacother 1993;27:316-21.
105. Rubenstein E, Engel N. Successful treatment of transvestic fetishism with sertraline and lithium. J Clin Psychiatry 1996;57:92.
106. Sherak DL. Pharmacological treatment of sexually offending behavior in people with mental retardation/developmental disabilities. Mental Health Aspects Developmental Disabilities 2000;3:62-74.
107. Stewart JT, Shin KJ. Paroxetine treatment of sexual disinhibition in dementia. Am J Psychiatry 1997;154:1474.
108. Waldinger MD, Hengeveld MW. Neurosexuology and sexual psychopharmacology. Tijdschrift Voor Psychiatrie 2000;42:585-93.
109. Zohar J, Kaplan Z, Benjamin J. Compulsive exhibitionism successfully treated with fluvoxamine: A controlled case study. J Clin Psychiatry 1994;55:86-8.
110. Zonana H, Norko M. Sexual predators. Psychiatr Clinics North Am 1999;22:109-27.